Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 30, 2026 | clinicaltrials |
| NCT07848295 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | not yet recruiting | Phase 1 | 112 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 7 | Sep 30, 2026 |
| clinicaltrials |
| NCT07848360 | Traction-Assisted Versus Conventional Endoscopic Submucosal Dissection for Rectal Neuroendocrine Tumors(TRACE-NET) | not yet recruiting | N/A | 66 | Pusan National University HospitalOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07848568 | Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 70 | Children's Oncology GroupNETWORK | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07848750 | InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | recruiting | — | 40 | Beijing Municipal Administration of HospitalsOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848815 | Risk-Based Lung Cancer Detection in COPD Patients(ELUCID) | recruiting | N/A | 1,000 | Vejle HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848828 | Autonomic and Renal Contributions to Hypertension With ADT(ARCH) | recruiting | Phase 4 | 50 | Virginia Commonwealth UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848841 | Online Perioperative Education Program on Patient Satisfaction and Clinical Outcomes for Head and Neck Surgery | recruiting | N/A | 50 | Washington University School of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848854 | Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples | recruiting | Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849231 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms(CLARITY-101) | recruiting | Phase 1 | 250 | Damora TherapeuticsINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849400 | Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery | not yet recruiting | N/A | 566 | Diansan SuOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849543 | Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study | not yet recruiting | N/A | 190 | Thomas Jefferson UniversityOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07849608 | Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer | recruiting | — | 200 | Qun ZhaoOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849660 | Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | active not recruiting | — | 170 | Eisai Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849712 | An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer(BEACON-OLD) | not yet recruiting | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850284 | SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850336 | Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment(PERFECT) | not yet recruiting | N/A | 56 | Bojan KovacevicOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07850453 | Vortosiran for VTE Prevention | not yet recruiting | Phase 2 | 150 | Ribocure Pharmaceuticals ABINDUSTRY | 4 | Sep 30, 2026 | clinicaltrials |
| NCT07850778 | ONS USE IN COLON CANCER(ONS COLON CA) | completed | — | 209 | Osmaniye Korkut Ata UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850791 | A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer | recruiting | Phase 2 | 38 | Haitao Zhao, MDOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850921 | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | not yet recruiting | Phase 1 / Phase 2 | 192 | Regeneron PharmaceuticalsINDUSTRY | 0 | Sep 30, 2026 | clinicaltrials |
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | completed | Phase 3 | 1,150 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Sep 29, 2026 | clinicaltrials |
| NCT00027326 | Collection of Blood and Urine From Patients Undergoing Radiation Therapy | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00423644 | A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b | completed | Phase 2 | 17 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00496522 | Proton Beam Therapy for Chondrosarcoma | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00591422 | Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas | completed | Phase 1 | 23 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00592163 | Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 20 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00607711 | Study of Oral Palifosfamide Tris in Solid Tumors | withdrawn | Phase 1 | 0 | Alaunos TherapeuticsINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT00924196 | Natural History Study of Patients With Neurofibromatosis Type I | active not recruiting | — | 259 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01230866 | Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer | active not recruiting | Phase 3 | 150 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01414855 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | completed | Phase 2 | 100 | Genentech, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01492972 | Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | recruiting | Phase 3 | 192 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01559935 | Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma(CarBiRD) | completed | Phase 2 | 74 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01758445 | Proton Radiation for Stage II/III Breast Cancer | active not recruiting | Phase 2 | 220 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01766297 | Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer | recruiting | Phase 2 | 132 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01824875 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 144 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02345265 | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 579 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | active not recruiting | Phase 2 / Phase 3 | 582 | National Cancer Institute (NCI)NIH | 5 | Sep 29, 2026 | clinicaltrials |
| NCT02595944 | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)(ANVIL) | active not recruiting | Phase 3 | 903 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02598349 | Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | recruiting | Phase 2 | 60 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02613819 | Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney(FASTRACK II) | completed | Phase 2 | 71 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02743741 | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors | completed | N/A | 195 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02893397 | Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer | active not recruiting | N/A | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 30, 2026source: clinicaltrials